Table 1 Characteristics And Pneumococcal VCR (%) Of Individuals Aged 18–64 Years With Newly Diagnosed Underlying Medical Conditions (CPRD; 2011–2015)
Total | Pneumococcal vaccine in the 1-year follow-up | P-value | VCR | ||
|---|---|---|---|---|---|
N (%) | N (%) | (%) | |||
Yes | No | ||||
Total | 99,153 (100) | 13,518 (100) | 85,635 (100) | 13.6 | |
Age | <.0001 | ||||
Mean years (SD) | 51.8 (10.1) | 52.8 (9.5) | 51.7 (10.2) | ||
18–49 | 33,210 (33.5) | 4143 (30.7) | 29,067 (33.9) | 12.5 | |
50–64 | 65,943 (66.5) | 9375 (69.4) | 56,568 (66.1) | 14.2 | |
Gendera | 0.0304 | ||||
Male | 56,139 (56.6) | 7770 (57.5) | 48,369 (56.5) | 13.8 | |
Female | 43,009 (43.4) | 5748 (42.5) | 37,261 (43.5) | 13.4 | |
Region | <.0001 | ||||
North East | 1366 (1.4) | 126 (0.9) | 1240 (1.5) | 9.2 | |
North West | 11,777 (11.9) | 1727 (12.8) | 10,050 (11.7) | 14.7 | |
Yorkshire and The Humber | 1672 (1.7) | 290 (2.2) | 1382 (1.6) | 17.3 | |
East Midlands | 520 (0.5) | 75 (0.6) | 445 (0.5) | 14.4 | |
West Midlands | 8743 (8.8) | 1363 (10.1) | 7380 (8.6) | 15.6 | |
East of England | 4959 (5.0) | 712 (5.3) | 4247 (5.0) | 14.4 | |
South West | 7188 (7.2) | 947 (7.0) | 6241 (7.3) | 13.2 | |
South Central | 9143 (9.2) | 1249 (9.2) | 7894 (9.2) | 13.7 | |
London | 10,381 (10.5) | 1295 (9.6) | 9086 (10.6) | 12.5 | |
South East Coast | 9210 (9.3) | 1137 (8.4) | 8073 (9.4) | 12.3 | |
Northern Ireland | 4312 (4.3) | 613 (4.5) | 3699 (4.3) | 14.2 | |
Scotland | 15,241 (15.4) | 2676 (19.8) | 12,565 (14.7) | 17.6 | |
Wales | 14,641 (14.8) | 1308 (9.7) | 13,333 (15.6) | 8.9 | |
Individuals with one underlying medical conditionb | <.0001 | ||||
Cerebrospinal fluid leaks | 211 (0.2) | 15 (0.1) | 196 (0.2) | 7.1 | |
Chronic heart disease | 18,103 (18.3) | 2228 (16.5) | 15,875 (18.5) | 12.3 | |
Chronic kidney disease | 1871 (1.9) | 162 (1.2) | 1709 (2.0) | 8.7 | |
Chronic liver disease | 2697 (2.7) | 199 (1.5) | 2498 (2.9) | 7.4 | |
Chronic respiratory disease | 22,367 (22.6) | 3110 (23.0) | 19,257 (22.5) | 13.9 | |
Diabetes mellitus | 40,035 (40.4) | 5775 (42.7) | 34,260 (40.0) | 14.4 | |
Immunosuppression | 10,125 (10.2) | 1340 (9.9) | 8785 (10.3) | 13.2 | |
Influenza vaccine use in the first year of follow-up | <.0001 | ||||
No | 35,405 (35.7) | 887 (6.6) | 34,518 (40.3) | 2.5 | |
Yes | 63,748 (64.3) | 12,631 (93.4) | 51,117 (59.7) | 19.8 | |